Guillon Benoit, Ecarnot Fiona, Marcucci Charles, Ducloux Didier, Chatot Marion, Badoz Marc, Bonnet Benjamin, Chopard Romain, Frey Pierre, Meneveau Nicolas, Schiele François
Department of Cardiology, University Hospital Besancon, and EA3920, University of Burgundy-Franche-Comté, Besancon, France.
Department of Nephrology, University Hospital Besancon, Besancon, France.
Am J Cardiol. 2018 Apr 1;121(7):818-824. doi: 10.1016/j.amjcard.2017.12.029. Epub 2018 Jan 9.
We assessed incidence, predictors, and impact on 6-month mortality of contrast-induced acute kidney injury (CI-AKI) after coronary angiography with or without percutaneous coronary intervention in patients with acute coronary syndrome (ACS), according to 3 different CI-AKI definitions. Serum creatinine (sCr) was assessed at baseline and 48 to 72 hours after procedure to classify patients into 3 CI-AKI groups: Group 1: increase in sCR ≥25% over baseline but absolute increase <0.5 mg/dl; Group 2: absolute increase ≥0.5 mg/dl; Group 3: absolute increase ≥0.3 mg/dl or ≥50% over baseline. The association between CI-AKI and all-cause 6-month mortality was assessed using multivariate Cox regression. Among 1,002 patients included, median age was 68 [57 to 79] years. The sample had the following characteristics: 70% men, 25% diabetics, 22% had a history of myocardial infarction, 21% had baseline estimated glomerular filtration rate (as calculated by the Modification of Diet in Renal Disease) <60 ml/min/1.72 m, 34% had ST-segment elevation myocardial infarction, 61% underwent percutaneous coronary intervention, and 43% had multivessel disease. Based on changes in sCr, 89 patients (8.9%) were classified in Group 1; 69 (6.9%) in Group 2; and 157 (15.7%) in Group 3, whereas sCr did not increase >25% in the remaining 844 (84.2%). CI-AKI was significantly associated with 6-month all-cause mortality using the definitions for Group 2 (hazard ratio 3.1, 95% confidence interval [CI] 1.5 to 6.6, p = 0.002) and Group 3 (hazard ratio 2.03, 95% CI 1.03 to 4.0, p = 0.04), but not Group 1. In conclusion, based on the definition used for CI-AKI, CI-AKI is observed in 6% to 15.7% of patients. An increase of 25% over baseline sCr does not identify high-risk patients. CI-AKI defined as an increase in sCr >0.3 mg/dl identifies 15.7% of the population at 2-fold higher risk of mortality.
我们根据3种不同的造影剂诱导的急性肾损伤(CI-AKI)定义,评估了急性冠状动脉综合征(ACS)患者在接受或未接受经皮冠状动脉介入治疗的冠状动脉造影术后CI-AKI的发生率、预测因素及其对6个月死亡率的影响。在基线时以及术后48至72小时评估血清肌酐(sCr),以将患者分为3个CI-AKI组:第1组:sCR较基线升高≥25%但绝对升高<0.5mg/dl;第2组:绝对升高≥0.5mg/dl;第3组:绝对升高≥0.3mg/dl或较基线升高≥50%。使用多变量Cox回归评估CI-AKI与6个月全因死亡率之间的关联。在纳入的1002例患者中,中位年龄为68[57至79]岁。样本具有以下特征:70%为男性,25%为糖尿病患者,22%有心肌梗死病史,21%的患者基线估计肾小球滤过率(根据肾脏疾病饮食改良法计算)<60ml/min/1.72m²,34%为ST段抬高型心肌梗死,61%接受了经皮冠状动脉介入治疗,43%有多支血管病变。根据sCr的变化,89例患者(8.9%)被归类为第1组;69例(6.9%)为第2组;157例(15.7%)为第3组,而其余844例(84.2%)患者的sCr升高未超过25%。使用第2组(风险比3.1,95%置信区间[CI]1.5至6.6,p = 0.002)和第3组(风险比2.03,95%CI 1.03至4.0,p = 0.04)的定义时,CI-AKI与6个月全因死亡率显著相关,但第1组不相关。总之,根据用于CI-AKI的定义,6%至15.7%的患者出现CI-AKI。sCr较基线升高25%并不能识别高危患者。定义为sCr升高>0.3mg/dl的CI-AKI可识别出死亡率风险高出两倍的15.7%的人群。